YouTubeFeed
← This Week in Startups

Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315

71:44 1.2K views 2026-07-23 Watch on YouTube ↗

Why this longevity startup raised in Japan, not Silicon Valley | TWiST Tokyo | E2315

Summary

This is a special TWiST Tokyo taping, recorded live in front of about 40 founders at the second Founder University Japan cohort. Jason Calacanis solo-hosts (no Lon Harris this episode) and interviews Bilal Kharouni, a French ex-martial-artist turned founder of Ekei Labs, a longevity startup that generates high-resolution, low-cost epigenetic (DNA methylation) data for drug discovery and cell-therapy manufacturing quality control. The two dig into why the moat in AI-for-biology isn’t the model but the proprietary data behind it, Bilal’s prediction that “virtual cell organisms” are the next AlphaFold-style breakthrough, and a wide-ranging detour into the ethics of experimental medicine — “right to try” laws, off-menu stem cell tourism, and a hypothetical about volunteers intentionally getting infected with COVID to advance research.

The back half turns into a tactical company-building session built around the video’s title question: why Ekei raised roughly $200K in Japan rather than $2M in San Francisco. Bilal walks through Japan’s stacked capital sources (VCs, angels, and government-guaranteed low-interest startup loans), the 2013 Regenerative Medicine Law that fast-tracks cell and gene therapy, and why US biotech VCs are stunned by what a $200K Japanese raise can accomplish. He also explains why Ekei killed a growing, cash-generating clinic-testing business to stay focused on core R&D — trading short-term revenue for long-term IP value — and the two discuss Blue Zones skepticism (some Okinawan “supercentenarians” turned out to be dead, with families collecting pensions) versus the more durable finding that social connectivity extends lifespan.

The episode closes with a live Q&A from Founder University attendees, covering focus discipline, Amazon’s “bar raiser” hiring framework, social robots and loneliness, and Silicon Valley’s 996 hustle culture. (Editorial note: the interview-transcriber was seeded with only two speakers, Jason Calacanis and Bilal Kharouni, since the episode description didn’t name additional participants. During the live Q&A segment starting around 50:11, several questions were actually asked by unidentified Founder University audience members using a shared microphone, but the diarization attributed them to Jason or Bilal by default. Five segments — at 50:25, 56:39, 62:46, 63:00, and 63:51 — have been relabeled “Audience Member” below based on content review, since their phrasing (“Hello, thank you for the talk…”, “Hey, thank you very much for the session…”) and first-time-introduction framing make clear they are not Jason or Bilal speaking. The individual audience members’ names were not captured or announced.)

Highlights

”In AI for biology, the moat is in data generation”

Bilal Kharouni on why data, not models, is the moat in AI biology

“If you use public data, it’s not going, it wasn’t built for your phenotype, it was not built for the indication your model targets and unfortunately you cannot really model your way out from a data set that isn’t there.” — Bilal Kharouni, 7:52

Clip command
yt-dlp --download-sections "*7:52-8:40" "https://www.youtube.com/watch?v=207qq4jwrUY" --force-keyframes-at-cuts --merge-output-format mp4 -o "data-generation-moat.mp4"

”This person has given more to the advancement… he saved thousands of lives”

Jason Calacanis tells the story of the man who injected himself with snake venom

“There’s a guy who… collected venomous snakes and injected himself with the snake venom to build up a tolerance for it. Over time… his blood plasma was able to create [antidotes] for poisons like this and toxins… He saved thousands of lives I believe.” — Jason Calacanis, 22:48

Clip command
yt-dlp --download-sections "*22:48-23:35" "https://www.youtube.com/watch?v=207qq4jwrUY" --force-keyframes-at-cuts --merge-output-format mp4 -o "snake-venom-guy.mp4"

”A Japanese startup that raised 200k… US biotech VCs are quite amazed”

Bilal Kharouni on why $200K in Japan out-builds $2M in San Francisco

“More and more US biotech VCs come to Japan and they’re quite amazed at what a Japanese startup that raised 200k they were able to accomplish, right? They look at the data and that was only made with this amount of resources. So I think it’s something that we can be really proud of in Japan is how much we can achieve with sometimes a really small resources.” — Bilal Kharouni, 33:04

Clip command
yt-dlp --download-sections "*33:04-33:54" "https://www.youtube.com/watch?v=207qq4jwrUY" --force-keyframes-at-cuts --merge-output-format mp4 -o "200k-japan-raise.mp4"

”We decided to completely terminate this business”

Bilal Kharouni on killing a profitable service to stay focused

“We actually had quite some growth with the clinics, a lot of prospect, a lot of meetings, but we decided to completely terminate this business. And the reason why was because it felt like a distraction from what will really make the value of the company explode, which is the race for data generation.” — Bilal Kharouni, 40:05

Clip command
yt-dlp --download-sections "*40:05-41:08" "https://www.youtube.com/watch?v=207qq4jwrUY" --force-keyframes-at-cuts --merge-output-format mp4 -o "ekei-killed-the-business.mp4"

”Some people… that we estimated to be 118 years, were just dead”

Bilal Kharouni on the Blue Zones pension-fraud controversy

“They went, did some field trip, and they realized that some people, for example, that we estimated to be 118 years, were just dead and people were collecting the pension of the family, for example.” — Bilal Kharouni, 46:58

Clip command
yt-dlp --download-sections "*46:58-47:40" "https://www.youtube.com/watch?v=207qq4jwrUY" --force-keyframes-at-cuts --merge-output-format mp4 -o "blue-zones-pension-fraud.mp4"

”I am ruthless about my time”

Jason Calacanis on ruthless time management as a founder

“I am ruthless about my time. I do not waste time on phone calls… I just want the best price and I’ll make a quick decision. If you want to share anything with me, make a Loom, like please.” — Jason Calacanis, 68:27

Clip command
yt-dlp --download-sections "*68:27-69:13" "https://www.youtube.com/watch?v=207qq4jwrUY" --force-keyframes-at-cuts --merge-output-format mp4 -o "ruthless-about-time.mp4"

Key Points

  • Founder University’s second Tokyo cohort, live audience (0:00) - Jason solo-hosts a live taping in front of ~40 founders; Founder University is Launch’s pre-accelerator, run on three continents (Japan, Saudi Arabia, USA).
  • Ekei Labs: epigenetic data for drug development and cell-therapy QC (3:45) - Generates high-resolution, low-cost DNA methylation data; paid for aging discovery research and for manufacturing quality control of stem cell batches.
  • “In AI for biology, the moat is in data generation” (7:52) - Public datasets weren’t built for a specific phenotype or indication; Ekei starts from proprietary data, then applies relatively simple models like elastic regression.
  • Prediction: “virtual cell organisms” are the next AI-bio frontier (9:00) - Bilal compares the coming breakthrough to AlphaFold; once virtual cell models exist, new drugs “will be absolutely groundbreaking.”
  • Japan’s 2013 Regenerative Medicine Law fast-tracks cell/gene therapy (24:15) - Enacted after Dr. Shinya Yamanaka’s 2012 Nobel Prize for pluripotent stem cells; gives Japan access to therapies unavailable in the more conservative US FDA framework.
  • Why Okinawa: OIST, not just the Blue Zone effect (26:00) - Ekei’s lab bench is at the Okinawa Institute of Science and Technology (English-language, 50% international PhD researchers), reporting directly to the PM’s office.
  • Raising in Japan: VCs, angels, plus government-guaranteed startup loans (30:02) - Banks back low-interest, long-term loans with government guarantors, letting Ekei stack non-dilutive capital on top of equity to keep the cap table clean.
  • US biotech VCs stunned by a $200K Japanese raise (33:04) - Ekei stretched $200K to results American VCs assume take millions; the title’s central thesis on capital efficiency.
  • Founders can “flip” to Delaware at exit or IPO time (34:42) - Raise cheaply as a Japanese entity, then incorporate in the US (Delaware, Texas, or Nevada) when it’s time to access US investors or go public.
  • Tokyo Stock Exchange tightened IPO rules to curb “zombie” companies (35:43) - The old Series-B-sized IPO bar (as little as $5-10M revenue) was raised, pushing the ecosystem toward M&A as the primary exit path.
  • Killed a growing, profitable clinic-testing business to stay focused (40:05) - Ekei walked away from recurring cash revenue from longevity clinics to concentrate fully on the core data-generation platform and its IP.
  • Trading short-term revenue for long-term equity value (42:00) - Jason frames the classic founder tension: extending runway with quick revenue vs. building toward a billion-dollar outcome; angels vs. VCs often disagree on which to prioritize.
  • Biological age scores are directional, not something to “game” (43:57) - Bilal warns that optimizing a Whoop or Oura biomarker can disconnect from actual health; more useful for population-level trends and clinical trial design than personal life-hacking.
  • Blue Zones controversy: some “118-year-olds” were dead, families collecting pensions (46:58) - Researchers found many Blue Zones were the poorest regions in their countries, and some record-age claims traced to pension fraud rather than real longevity.
  • Socialization as a genuine longevity driver in Okinawa (47:51) - Regular contact and community support correlate with healthier aging; Bilal has seen people decline rapidly when long-standing support networks disappear.
  • Founder Q&A: killing revenue requires discipline, not just data (50:25) - An audience member presses Bilal on whether the decision to cut a cash-generating service was data-driven; Bilal says the books alone would have argued to keep it — it was a strategic focus call.
  • Amazon’s “bar raiser” hiring framework (55:03) - Jason explains hiring people whose knowledge exceeds the team’s baseline in a given area, so every new hire raises the organization’s overall bar.
  • Founder Q&A: could social robots reduce loneliness-driven aging? (62:46) - An audience member (revealed to run a robotics/companion-software startup) asks whether a sufficiently capable social robot could measurably improve biomarkers of aging; Bilal says yes, if it creates a genuine “feeling of care.”
  • Jason on ruthless time management and hustle culture (68:27) - Works 60-70 hours a week but protects sleep and family dinners; argues efficiency beats hours, and that being unhealthy (he was once 40 lbs heavier) degrades a founder’s thinking.

Mentions

Companies

  • Ekei Labs (3:00) - Bilal Kharouni’s longevity startup generating epigenetic data for drug discovery and cell-therapy QC; based in Tokyo (business/fundraising) and Okinawa (R&D lab).
  • Life Biosciences (11:26) - Dr. David Sinclair’s company; cited as running the first clinical trial for a drug that might actually reverse aging.
  • New Limit (12:00) - Epigenetic reprogramming company funded by former Coinbase CEO Brian Armstrong.
  • Okinawa Institute of Science and Technology (OIST) (26:00) - English-language, PM’s-office-affiliated research institute that supplies Ekei’s R&D talent pipeline.
  • Sentry (9:24) - Sponsor; AI debugging agent for application errors, $240 in credits via sentry.io/twist.
  • Agree.com (21:54) - Sponsor; contract-to-cash workflow platform, 50% off for life for TWiST listeners.
  • Northwest Registered Agent (30:32) - Sponsor; Delaware C-Corp formation service.
  • Tokyo Stock Exchange (35:35) - Raised its listing bar to reduce “zombie” public companies, pushing later-stage startups toward M&A exits.
  • Google / Meta / Uber / Airbnb / Coinbase / SpaceX / Anthropic / OpenAI (36:29) - Cited by Jason as the cutthroat equity-chasing circuit US tech employees hop between; contrasted with Japan’s less mercenary equity culture.
  • Amazon (55:03) - Source of the “bar raiser” hiring framework Jason describes.
  • Sequoia (61:03) - Jason cites partner Roelof Botha’s line: “great companies are bought, not sold.”
  • Dropbox (61:58) - Jason references Steve Jobs personally calling founder Drew Houston as an example of “you know when it’s happening.”

Products & Technologies

  • Epigenetic / DNA methylation data platform (3:45) - Ekei’s core technology: reading chemical tags on DNA that switch genes on/off, at high resolution and low cost.
  • Whoop (43:00) - Wearable Jason uses that scores sleep-pattern consistency as a proxy for biological age.
  • Oura Ring (43:57) - Bilal says he’s stopped wearing his because it encourages gaming biomarkers disconnected from real health.
  • Superpower / Function Health (43:00) - Blood-testing services Jason uses that produce a separate biological-age estimate from his Whoop data.
  • Retatrutide (15:25) - Unapproved GLP-1 drug Jason says people are already sourcing quietly from compounding pharmacies.

People

  • Bilal Kharouni (2:43) - Guest; French ex-martial-artist, founder of Ekei Labs, based between Okinawa and Tokyo.
  • Dr. Shinya Yamanaka (4:18) - Nobel laureate credited with the pluripotent stem cell breakthrough that seeded Japan’s regenerative medicine industry.
  • Dr. David Sinclair (11:26) - Longevity researcher behind Life Biosciences’ anti-aging drug trial.
  • Brian Armstrong (12:00) - Former Coinbase CEO; funds New Limit.
  • Kobe Bryant (14:08) - Cited by Jason as an example of athletes using blood-plasma/stem-cell treatments after injury.
  • Lina Khan (36:29) - Former FTC chair Jason says blocked M&A activity during the Biden administration.
  • Roelof Botha (61:03) - Sequoia partner; source of the “great companies are bought, not sold” line.
  • Steve Jobs / Drew Houston (61:58) - Referenced in Jason’s story about Jobs personally calling the Dropbox founder.
  • PM Sanae Takaichi (64:16) - Japanese Prime Minister (Bilal refers to her as “Takeuchi” in the audio) cited for reportedly sleeping 0-3 hours a night.

Surprising Quotes

“They went, did some field trip, and they realized that some people, for example, that we estimated to be 118 years, were just dead and people were collecting the pension of the family, for example.” — Bilal Kharouni, 46:58

“Unfortunately you cannot really model your way out from a data set that isn’t there.” — Bilal Kharouni, 7:52

“More and more US biotech VCs come to Japan and they’re quite amazed at what a Japanese startup that raised 200k they were able to accomplish.” — Bilal Kharouni, 33:04

“This person has given more to the advancement and more people have survived venomous snake attacks because of this individual. He saved thousands of lives I believe.” — Jason Calacanis, 22:48

“I am ruthless about my time. I do not waste time on phone calls… I just want the best price and I’ll make a quick decision.” — Jason Calacanis, 68:27

Transcript

Jason Calacanis: 0:00 All right everybody, I am back in Japan for Founder University Japan which is our second cohort and I’m here with a live audience which you’re going to hear roar and clapping right now. And then I’m going to teach you guys how to round out the clap. This is very important. You’re going to clap like crazy like you won the lottery, but then I’m going to go and as it comes down boom nice and sharp you stop. Okay, we’ll try it one more time. I’m here with a live studio audience in Tokyo. Could be better. Let’s try it one more time. I’m live with a studio audience here in Tokyo. Perfect. What we like to do when I’m in Japan is meet some founders working on interesting things who are a little further ahead than the Founder University cohort. What is Founder University? Founder University is a pre-accelerator. It comes before Techstars, Y Combinator, or the Launch accelerator. Many of our companies have gone on to A16 speedrun, Techstars, etc, Y Combinator of course, and our program, Launch Accelerator. We run the Founder University program on three continents now. Here in Japan, we do it in Saudi Arabia in Riyadh twice a year with our friends at Sanabil, the PIF. And we do it of course in America, internationally. What is Founder University? As a pre-accelerator we help teams work on product market fit, raising their first round of capital. We have thousands of people apply a year for a couple of hundred spots. The program is 12 weeks long. We ask everybody to work really hard for those 12 weeks to try to make amazing progress on their products, on their teams, and in working with their customers. A startup in its most basic form is those three things. A team that develops a product that delights a customer base. And if you get that flywheel going, everything is really easy. Now, of course, most startups fail, but if you in the course of your career decide to do two, three, four startups, you’re going to hit success. And so we love as a firm, the Launch Fund, which I run and we’re now on our fourth fund, we love to work with early stage founders. We’ve been so lucky to hit, you know, just some world-changing startups of course Uber, Robinhood, Calm, Thumbtack, Athena, Zipline, Vast Space. So many great companies and a lot of new AI companies that have suddenly become worth hundreds of millions of dollars, billions of dollars, like Abacus or Micro1. Those are recent ones that you will be hearing about in the future. Because we’re here live with a bunch of founders in the room, about 40 of them, we’re going to talk about some topics today in terms of company building with our guest and we’re also going to hear about his startup. So our guest today is Bilal Kharouni.

Bilal Kharouni: 2:56 Kharouni.

Jason Calacanis: 2:57 Yes, Kharouni. Now you have a French accent, not a Japanese one. Your… Your company is Ekei Labs. That’s spelled E-K-E-I-L-A-B-S.com. You can go visit it. You’re a longevity startup. And everybody’s talking about longevity. We’ll talk about company building, everything from product-market fit to operating a company here in Japan, hiring people in Japan, cap tables, and all of those great things. But I want to start with your business and what you’re doing. So Ekei Labs, what is the mission? And how are you going after this very important space, which is longevity? I’m sure it is by design that you’re here in Japan where we have some of the longest lifespans and we have a massively aging population. So tell us just a bit about Ekei Labs.

Bilal Kharouni: 3:45 Yeah. So to start with Ekei Labs, we generate high-resolution and low-cost epigenetic data for drug development. Today we’re getting paid for discovery on aging, as well as for manufacturing quality control in cell therapy. Our mission is really to build an infrastructure for data generation to help advancing longevity research.

Jason Calacanis: 4:04 So there’s a bunch of people who are doing longevity research. Who are those people? Pharmaceutical companies, startups, big company, small companies. Tell us a little bit about your customers, your partners.

Bilal Kharouni: 4:18 Um, so we work with one of the largest life science conglomerates here in Japan. And we also work with early-stage biotech startups and startups that are quite advanced and already manufacturing their own cell therapies. And you were mentioning one of the many reasons for longevity company to be here in Japan. But one of them on top of the aging society is the regenerative medicine space. Some of the best innovations have been created here in Japan. We can cite the Nobel Prize, Dr. Shinya Yamanaka, who created a new way to generate stem cells to make it very simple. And we are very lucky to be working with some of the startups that were born from this movement and are extremely innovative here in Japan.

Jason Calacanis: 4:58 Now tell us a little bit about the product. You’ve been working on it for three or four years now and it’s in market. You have paying customers. So what is this product exactly? And why don’t they build it themselves? I guess is always the question. So tell us a little bit about the innovation in terms of the product you’re building. And you can get a little technical and I’ll help translate since I am not a investor in biotech companies.

Bilal Kharouni: 5:29 Great. Um, so to make it quite simple on what our service is, is we generate epigenetic data that don’t exist yet for whoever wants to get a decision from it. So what is epigenetic?

Jason Calacanis: 5:45 Epigenetic.

Bilal Kharouni: 5:46 Epigenetic, yeah. So we do not look at all of the DNA code. We look at a layer above it that silence or express genes. Now this signal is very important because it changes with aging, it changes with therapeutic responses. And we have our own methods to read the methylation and which is a subset of epigenetics. Epigenetics, methylation is some chemical tags that go on the DNA that switch certain genes on and off. And we have a way to read this signal in a way that is incredibly high resolution and at an incredible low cost.

Jason Calacanis: 6:15 So it’s a tool that let’s you look at this layer above the DNA and understand how I’m aging. When do you start tracking somebody and is it a blood test that is done, I’m assuming?

Bilal Kharouni: 6:27 So we’re sample agnostic, we’ve worked with different sample types. And usually we work with our clients, they have access to a large cohort, and they want either to do fundamental research on aging, so understanding how those patterns in methylation change when aging, and also how they change with some therapeutic response.

Jason Calacanis: 6:46 Got it. So if I was in this cohort being studied by a drug company, you run tests on me as the patient and they typically have dozens of people in these trials?

Bilal Kharouni: 6:57 So we’re lucky enough to work with very large cohorts, with hundreds, sometimes thousands of participants. And yeah, so basically this is when I was telling that we’re getting paid on discovery on aging, this is our project. And also another area for which we’re getting paid and for which we have a lot of traction and interest is also for one bottleneck in cell therapy manufacturing, which is to answer three questions: is my batch potent? Is my batch what I think it is? And is it identical to the next one, is it really consistent? So we also run tests on different stem cell batches for the manufacturing quality control.

Jason Calacanis: 7:34 What is the impact of these drugs today and with AI now, I am assuming, accelerating the ability to make these new drugs and these new therapies, tell us a little bit about the state of the art today and where you think that will be in five to ten years.

Bilal Kharouni: 7:52 Today, it’s quite exciting. We’ve had our first AI designed drugs that reached phase three in the regulatory layer. And so what we do is we generate data that’s never been generated before using our technology, and then we use it to create new models for clients. The reason we are generating and we are in the data generation business is because in AI for biology, the moat is in data generation. If you use public data, it’s not going, it wasn’t built for your phenotype, it was not built for the indication your model targets and unfortunately you cannot really model your way out from a data set that isn’t there. So we start from the start with the data generation, then we use relatively simple AI models like elastic regression to offer models either for like the discovery but also for other aspects of the drug development like patient stratification, making sure that your clinical trial is going to enroll the right patients or for the manufacturing QC. So today, it’s really exciting, we have our first drugs that’s been designed by AI that are going above the regulatory rank, and my prediction is that the next frontier for AI modeling will be a virtual cell organism. So currently data is being generated to try to find those models and to have a next AlphaFold breakthrough. And once we will have those virtual cell models, the new drugs that will hit the market will be absolutely groundbreaking.

Jason Calacanis: 9:24 It’s the worst nightmare of every founder. You’ve built a product, everything’s working great, then real users start flooding in and suddenly it all breaks. What a disaster! You need to get it back up and running, and you gotta do that fast. You’re looking like an amateur. That’s why you need a partner like Sentry. Applications can break in many different ways, but Sentry sees everything. You’ll get all the relevant details like stack traces, commits, releases, and even the developers who pushed that problem code in the first place. With Sentry, you’re not going to be jumping around between different tools trying to figure out what happened. And Sentry’s AI debugging agent uses all this data and context to identify the root cause of the problem and suggest a fix. It can even take a look at your code before it ships and warn you if any problems are likely. Try Sentry for free. If you’re a This Week in Startups listener at sentry.io/twist, use the code TWIST for $240 in Sentry credits. Make sure you use that code, make sure you use that URL, sentry.io/twist, so they know your Uncle J-Cal sent you. Yeah, and so today, is it mostly when people do longevity, is it supplements? Is it anti-aging yet? Is it making my telomeres not get as short and maybe trying to reverse aging? What- because I hear from my friends, they like to do off-menu items. Things that you can’t do in America, so they go down to Mexico, Costa Rica, South Korea, and they do stem cells. And they, I guess, have blood plasma taken out, it’s spun, and there’s some blood plasma treatments. So there’s this idea of tourism based on longevity. I’m 55 now, I know it’s hard to believe, but people my age are getting really into this. Peptides, blood transfusions, and stem cells are the ones I hear most about. Tell us a little bit about who is going to benefit from this and how.

Bilal Kharouni: 11:26 So true. So in terms of longevity treatment, you have a really large umbrella from therapeutics to lifestyle-based interventions. And right now, there’s not really a consensus of what would actually work for the patients. And that’s why with Achelous, we want also to build an infrastructure that can actually measure aging to really be able to have clinical validations of those treatments. And actually, it’s quite exciting that in 2026, we’ve had the first clinical trial for a drug that might actually reverse aging. It’s Life Bioscience. from Dr. David Sinclair that you might be aware of, as well as New Limit that was funded by Brian Armstrong, former CEO of Coinbase. They’ve had great data and they should have the first clinical trial we hope by next year. So I think that’s really slowly moving from off-menu items to actual drugs that went through the FDA programs now targeting clinical indications that are not aging. But I hope that one day aging might be recognized by the FDA as a clinical indication and that we will have actual therapeutics that will be reviewed with the same scrutiny and with the same rigor for aging.

Jason Calacanis: 12:45 For the individuals I know who are going to Panama and going to South Korea and doing these stem cells, are they wasting their money? Is it legit or is it just like a fad, this stem cell research in your mind? Would you if you were my friend, and maybe we’re friends after this over time, would you advise me to follow them and do some of these things? Or would you tell me it’s a waste of money and if I had the money to waste, would you tell me if it makes you feel good do it but it’s probably not going to do anything? Be honest with me about stem cells and some of these things.

Bilal Kharouni: 13:21 So it’s quite similar. Stem cells can be and cell therapies in general can be absolutely amazing, but it really depends on what is the clinical indication that you’re going for. If it’s for general aging, I do believe that some treatments might be really beneficial for aging. But I’m not a medical doctor and also doing things off-menu and with your own will without like a framework and someone following you I think can be dangerous. And unfortunately we have, you know, there’s some bad stories of people having issues following those treatments and something that we need to be aware of that it’s not sometimes…

Jason Calacanis: 14:02 The efficacy is not there?

Bilal Kharouni: 14:03 Efficacy is not there and also the safety need to be really looked at.

Jason Calacanis: 14:08 Yeah, I was a little concerned when I had friends going to Panama or going to Mexico and doing this. But they had nothing to lose was kind of the situation, they were sick or they had some indications. And then other ones are doing it because maybe they have a knee that had meniscus surgery or a torn ACL. And I have heard that some folks, Kobe Bryant has gone, rest in peace, but Kobe Bryant went when he tore his Achilles or shoulder, whatever it was. And a lot of NBA players went to clinics in Germany, I believe, to do this blood plasma kind of stuff and I know you’re not a doctor and may not be your specialty, but there is some efficacy there?

Bilal Kharouni: 14:51 100 percent. So that’s what I was, where I was drawing the line, is if it’s not following a clinical indication and just for general wellness and aging at the moment, I have… not sure of the scientific consensus, but if you look at a clinical indication, I 100% believe that can be part of a medical journey. That’s tremendous value. And the other thing when you’re mentioning your friend that had nothing to lose, I’m also a huge believer in the right to try. Um, some states in the US are really pushing for this right, that for patients that unfortunately don’t have another solution to have access to care that’s sometimes un-

Jason Calacanis: 15:25 I mean, right to try, it’s pretty explanatory in the name. You have the right to try a drug. It’s your choice as a human on planet Earth to take that risk. But explain legally the framework as best you can for us as laypeople. You know, if a state decides to do this, what’s the practical implication of it? We heard that there’s somebody high profile who’s 80 years old in the United States, who has some issues, uh, taking Retatrutide, this new, uh, you know, GLP. And people were speculating it was the president of the United States. You’ve heard this speculation. I, we have no way of knowing if it’s President Trump or not. But Retatrutide is not there yet. People are taking it already from compounding pharmacies. Someone who’s not me has experienced with it and said it’s pretty amazing. There are many people I know in the states who are taking Retatrutide very quietly. So maybe you could talk about what is exactly the right to try and why you believe in it, and do you believe in it also for young people who maybe aren’t sick, but want to try peptides, want to try Retatrutide before it’s approved, etc.?

Bilal Kharouni: 16:32 So the legal framework of the right to try is very complex, but it would be the right for if you have, for example, an incurable disease, you have the right to try a therapy like a cell therapy, a gene therapy that haven’t been approved yet, but you take the risk knowingly that might save your life. And you have politicians in the US more and more who having a movement to put that in law and give access to care that could save life to patients that would not have access to these cares in the current situation. So I think that’s absolutely a great things. Um, and now for the right to try for younger healthy people, I think that’s a very interesting ethical questions for doctors. Me personally, I mean, I’m an entrepreneur and I have like a sense of risk. So me for me personally, I would like to try like certain, um, certain therapies that are not on the market, that are not maybe scientifically approved, but that would be my, 100% my choice and the risk that I would be ready to take. But I can definitely understand that the ethical choice for a doctor to inject a drug to a patient who is healthy can be also hard to take for the for the doctors.

Jason Calacanis: 17:41 Yeah, but you believe, as an entrepreneur and maybe as somebody who is freedom-loving, uh, I think, and, uh, you were previously a martial artist who got injured, um, you say, hey, maybe, um, there’s a personal freedom here that should be allowed if the person goes in knowingly.

Bilal Kharouni: 17:59 Yeah.

Jason Calacanis: 18:00 And they’ve, you know, signed off on it that they want to take the risk. And there have been trials, I don’t know if they’re called challenge trials, where people could, during COVID, say, I’m okay with taking the risk of giving me COVID in advance, giving me a therapy, because I want to try to help the world. I’m willing to take a payment for that or I’m willing to do it for the good of society. Now, in America, this would be forbidden, but in other countries, my understanding is, if somebody wanted to say, yes, inject me with COVID and inject me with the cure, I want to do it for the good of society. This to me seems like a beautiful thing for somebody to do. Now, I would be concerned if it was a poor person who was doing it just for the money, because that would seem like, oh, we’re using a power imbalance, an economic imbalance there, so I have deep concerns about that ethically. But if somebody who, you know, was not destitute financially, and they went through multiple screenings with a psychologist, with a counselor, and they said, no, I, during the height of COVID, I would like to take the risk of getting COVID. I don’t—I think I’m a low-risk, healthy individual. What do you think about that category of, like, actually somebody joining something in that brave way, like being—it’s almost like being an astronaut or something, and, you know, you’re willing to risk going to the moon?

Bilal Kharouni: 19:23 Very interesting. I’ve never heard of this particular case of people getting sick to advance medical research. And for me, still, like, the ethical question of getting someone sick, even if it can advance the research, is maybe, like, a border that I would not cross. Yeah. But ethically, it’s a really fascinating one, right? Like, it’s very challenging. Yeah. And for me, it’s some—I think it’s a border that shouldn’t be crossed. But also I would question the motivation of the person who would be ready to get sick. So would it be truly—I mean, yeah, if the—if, as you mentioned, if it’s like space exploration, is really to advance human health, that would be an amazing motivation. But I would definitely also think about what would be the motivation. Do you know anyone in your personal circles that were ready to—

Jason Calacanis: 20:08 I mean, I don’t know anybody who would do that, but I could imagine if they were given compensation, if it was irreversible, so hey, if you do die from this, your family would get a million dollars or ten million dollars. If you were gonna get sick and there was some ongoing long-term COVID, let’s say, if you believe in long COVID, you would get free health care for life because of it. You know, as a society, we have people do many brave things. We have people who go to war. We have people who are firefighters who run into burning buildings. My brother was one of them, and he’s run into many burning buildings. Is there a difference between the bravery of an astronaut, the bravery of a firefighter, the bravery of a soldier, and the bravery of somebody who wanted to be part of advanced medicine to try to push the human spirit and the human and reduce human suffering? To me— You know, I’ve thought about it and I think, you know, I have nothing but respect for those people who choose to take those risks for the better of betterment of society, but I would be lying if I didn’t think it is ethically and morally challenging and has to be really well thought out and considered, which I think is what you’re saying as well.

Bilal Kharouni: 21:20 Um, yeah. It’s what I’m thinking. I think the ethical because I was thinking about the firefighter example which is great but for example we do not burn the skin of firefighters to then study how to do skin healing. So I think that’s where I would draw the line is that if we actually inoculate patients, healthy people with a disease to advance science, we do still deteriorate their health, which I think is a line that personally I would not cross.

Jason Calacanis: 21:54 Our show is filled with helpful and practical advice for founders, but there’s another reason to become a regular Twist listener. Amazing deals on essential products to help you run your company more effectively. So, I’m super excited to announce our new deal with agree.com, the all-in-one contract-to-cash workflow. Go right now to agree.com, sign up and tell them you’re a J-Cal listener and they’ll give you 50% off for life. Agree is the number one fastest way to go from contract to cash. That means gathering e-signatures, invoicing, billing, payments, and revenue recovery. No more jumping between four or five different platforms just to write out a contract, get it signed, then set up billing and start sending out invoices. 99.64% of all invoices on the entire platform are paid within just 10 days. So if you want to stop chasing invoices go right now to agree.com and if you tell them Jason sent you you’re gonna get 50% off for life. You want to talk about a crazy example? There’s a guy who, and we’ll put a link to it in our show notes, who collected venomous snakes and injected himself with the snake venom to build up a tolerance for it. Over time, after building it up, his blood plasma was able to create, I don’t know what they call the antidotes for poisons like this and toxins, but he moved that science forward. Now, he had done it on his own so that he would slowly build up a tolerance to this so he could handle his own snakes. But this person has given more to the advancement and more people have survived venomous snake attacks because of this individual. He saved thousands of lives I believe. So very interesting frontier we’re on now, huh?

Bilal Kharouni: 23:35 Yeah, no, I think that’s actually a great example, yes.

Jason Calacanis: 23:37 Um, tell me about the regulatory. Which modern societies have a very progressive thoughtful way of advancing this science given the risks? United States I think is the most conservative with the FDA or extremely conservative in the top 20% of conservative and then…

Bilal Kharouni: 24:00 the fairly conservative but you have more and more intention from the FDA to fast track cell therapy and gene therapy so that is still very early and also I am not a legal specialist especially of the US health care system

Jason Calacanis: 24:13 but other countries like South Korea, Japan

Bilal Kharouni: 24:15 Japan is very advanced so in 2012 Dr. Shinya Yamanaka won the Nobel Prize for discovery on pluripotent stem cells. In 2013 if I am not wrong the regenerative medicine law act was enacted and that’s really fast track cell therapy and gene therapies in Japan so in Japan we have access to numerous therapies that you do not have access to in the US and you have the really high quality medical care in Japan so I think that’s extremely interesting unique situation and that’s also one of the reason we are here with Ekei Labs.

Jason Calacanis: 24:54 When we get back from this quick break, I want to talk to you about company building here on this week in startups. Great job, that was awesome. All right, we’re here, we’re in Tokyo for Founder University our second cohort of Founder University in Tokyo. We’ve got an incredible guest. Bilal is here from Ekei Labs. You can go find out more at E-K-E-I-L-A-B-S dot com. Let’s talk about building a company. Why did you choose to place your company in here in Tokyo and I understand Okinawa?

Bilal Kharouni: 25:29 Yeah, so here in Tokyo and Japan is of course as you mentioning super age society, great legal framework to fast track regenerative medicine as well as great scientists and we work on aging we want to build an infrastructure to really accelerate aging research so in terms of like macro environment it makes a lot of sense and why Okinawa? So funny enough it’s one of the blue zone where the life expectancy is really high but this is not the reason we are there. The reason we are over there is because of the Okinawa Institute of Science and Technology that’s I don’t know if you’re familiar with.

Jason Calacanis: 25:59 tell us, yeah.

Bilal Kharouni: 26:00 It’s pretty unique so it depends directly from the prime minister office by status the language is in English 50% Japanese people 50% foreign people only from PhD graduates and it’s really a center of excellence for fundamental research, great science, great environment, great talents and we have located all of our R&D in Okinawa so we have our own lab bench so when we receive the samples from our clients it’s directly in our lab in Okinawa and now we have actually a great bridge from graduated academics from OIST to come and work directly for us with us so it’s a very great situation in which we do the business development, fundraising here in Tokyo and all of the science in Okinawa.

Jason Calacanis: 27:00 A little bit about, we get the talent base, right? So that’s great. You have a great customer base. You’ve got a great framework for regulations here. Those are all, I guess, wind in your sails, as opposed to headwinds, if you were in other places. Let’s talk about raising money in Japan versus the United States or other places. Now you were born in Paris, you spent time in Thailand, now you’re in Japan, so I just got back from Paris. Incredible. I forgot how amazing Paris is, and then you get to Tokyo and you’re like, wow, these are two of the great societies and you’ve got to live in both, yeah?

Bilal Kharouni: 27:36 Yeah, pretty lucky. So when was the last time you went to France and to Paris?

Jason Calacanis: 27:41 I probably, well, I was there like I said for two weeks, just recently and then before that it was about 10 years before that.

Bilal Kharouni: 27:48 It has changed quite a lot.

Jason Calacanis: 27:51 Yes, especially for the startup space.

Bilal Kharouni: 27:52 Yeah. They’re really cooking with oil, there’s a lot of great startup energy. And I think they’re becoming a little bit more flexible in terms of hiring people, firing people. There were some laws that made it very difficult to hire folks, or to take risks in hiring folks, because you couldn’t, if you were to start a division, and it was a very speculative division, you hire 10 people for it, you can’t just shut that division down. That’s why a lot of founders who were taking high risk startups maybe have a little bit of a challenge there, yeah?

Jason Calacanis: 28:23 Yeah, absolutely. And it changed a lot, like being regulatory space but also the amount of international funders and talents coming to Paris. I actually grew up 10 minutes from Station F and the whole…

Bilal Kharouni: 28:42 Station F is this beautiful old train station I believe or warehouse that’s been converted into a WeWork, a coworking facility.

Jason Calacanis: 28:49 Exactly. And the whole neighborhood has completely different from the time I grew up. So it’s definitely interesting to come back when I can.

Bilal Kharouni: 29:00 And you have a great startup community here that’s emerging, lots of talent. That’s why we’re here. We’re watching so many young folks and people who would have normally worked at a big company for life decide, hey, I’m going to try a startup and their parents are supporting them. I was talking with a journalist today, he’s Gen X as well and I asked him for his three kids, he had some kids who were 17 and 20 years old and I said, would you be happy if your kids took the risk of doing a company? He said, oh, I would be thrilled. Now he works for essentially the New York Times of Japan, so he’s you know, a business reporter. I said, would your parents as a Gen Xer, you know he’s got Gen Z kids, would your parents as a Gen Xer be happy if you started a company or would they be scared? He said, oh scared. They wouldn’t have wanted to. So we have this great moment where we have so many great founders here and they’re taking risks and they’re thinking globally. So that’s one of the nice things about how the startup communities have grown. Let’s talk really granularly about the investment community here. You have a number of great VCs, you have corporate VCs, and they also have grants. So you funded this company with a million dollars…

Jason Calacanis: 30:00 and some grants, yeah?

Bilal Kharouni: 30:02 Exactly. So we raised capital from Japanese VCs as well as from great Japanese angels. So not Japanese angels and as well as Europeans who have lived in Japan and led huge companies in Japan for decades. So we have very strong investors. And what is quite unique and what your audience especially in the US might be quite surprised is that we also had numerous startup loans.

Jason Calacanis: 30:32 Which is incredible. There are banks that have been given money by the government and allowed to take the risk of backing startups. So you’ve had a loan, I’m assuming a low interest loan over a long period of time? Tell us about it. Okay, so you’ve identified a real problem and you’ve put together a solid solution and a business model that you believe in. So you’re all set to launch your new company, right? Uh, not so fast. If you want investors and potential customers to take your new business seriously, you need to consider forming a Delaware C Corp. And that’s where Northwest Registered Agent comes in. They’re going to give your new company a real identity. That means an address for your public filings, a domain, a custom website, a business email and, of course, a phone number. And that’s going to take just 10 minutes and 10 clicks. They don’t charge hidden fees. Customer service is available around the clock. They’re not overwhelming your inbox with spam and they make it easy to cancel at any time. So get all the advantages of a Delaware C Corp independent regardless of where in the US you’re operating from. Visit northwestregisteredagent.com/twist for more details and the links are in the show notes.

Bilal Kharouni: 31:45 Yeah, exactly. So we’ve had different startup loans and as you mentioned, low interest over a long period of time. And more importantly, you have official institutions that are guarantors, which means that they also take the risk of granting the loan. And so you mentioned there’s a lot of great VCs in Japan, but the early stage funding is still sometimes slow and with small checks. And for us, it’s being able to leverage what we raise in equity to have more than what we raise, right? So we have one and then we’re going to have another one from the banks.

Jason Calacanis: 32:24 So for every dollar you raise you can get a bank dollar and then if you fight hard you might be able to get some grant money for this technology.

Bilal Kharouni: 32:32 Exactly.

Jason Calacanis: 32:33 Most angel investors here, what’s their check size and the range?

Bilal Kharouni: 32:43 I’ve really heard of everything and anything, you know, from a couple of thousand of dollars to a few like hundreds of thousands of dollars.

Jason Calacanis: 32:55 Okay, so you could have a 5k, 10k check, a 25k check, even a 100 or 200k check. So that’s lower than America and at lower valuations, but you raise less money per round because the cost of running a business here is significantly less. in San Francisco, yeah?

Bilal Kharouni: 33:01 Exactly, so you raise less, sorry that was your question.

Jason Calacanis: 33:04 Yeah.

Bilal Kharouni: 33:04 Yeah. So yeah, you raise less absolutely because definitely less expensive than running a startup in San Francisco. And also in our case, is we know that we can take the risk of raising less because we can add other source of non-dilutive funding, right? So we can keep a clean cap table and have more than what we raised for. And actually that’s quite interesting because more and more US biotech VCs come to Japan and they’re quite amazed at what a Japanese startup that raised 200k they were able to accomplish, right? They look at the data and that was only made with this amount of resources. So I think it’s something that we can be really proud of in Japan is how much we can achieve with sometimes a really small resources.

Jason Calacanis: 33:54 Well, and this will be an arbitrage opportunity. American VCs raise large funds, but they can take, make a couple of bets here at a lower valuation. The valuations in the United States have become disconnected from reality again. We had that happen previously in 2019, 2020 before COVID, they got disconnected during the SaaS period where they were giving people incredible valuations. So looking internationally you can find great teams that accomplish a lot on a small dollar amount. Then you have to look at, well, can they exit for a large amount of money? So you’re incorporated as a Japanese company or a Delaware company?

Bilal Kharouni: 34:34 So we are incorporated as a Japanese company. And we are talking more and more with US VCs and we might…

Jason Calacanis: 34:42 Flip.

Bilal Kharouni: 34:42 Flip, yeah.

Jason Calacanis: 34:44 Yeah, and the flip would then allow them if you were a Texas company, a Delaware company, even Nevada, those are the three ones that seem to be pretty popular right now in the United States, you would be able to raise from those VCs. So you as a founder can also do this arbitrage. You can raise from people who are less cost sensitive, you can run the company here, and then when it’s time for an exit or an IPO, you can become an American company. Yeah. And I don’t think the Japanese government has too much of a problem with that. They want to have more people here. I think they’d prefer you to be a Japanese company for now, but on an exit if you went public, that would be incredible for the Japanese society. And you can go public here on the Japanese stock market as well. Have you become educated with that?

Bilal Kharouni: 35:22 Yes, so actually the regulations have changed a lot to do an IPO. The Japanese Series B for a very long time used to be the IPO.

Jason Calacanis: 35:32 Incredible. With as little as 5 or 10 million in revenue.

Bilal Kharouni: 35:35 Exactly. So the Tokyo Stock Exchange actually stopped that and now…

Jason Calacanis: 35:40 Do you know why they stopped doing that? Was it because there were too many failures or…

Bilal Kharouni: 35:43 Yeah, I think there was too many like zombie companies on the stock market. And also I think that they want to encourage merger and acquisition as exit. And I think that will be really healthy, right? Because we were mentioning that the check signed by the angels are pretty low is because also we don’t have this… have a lot of founders that exited for a lot of cash and then that can really recirculate the money with angel investment. So now there’s a lot of restructuring, I think, being made with Japanese VCs and Japanese LPs because the question is if those startups cannot do an exit by IPO around like the series B timing, where do they get the growth funding and how do they exit? So that’s definitely interesting time in Japan for this.

Jason Calacanis: 36:29 Mergers and acquisitions would always be the second option for an exit for an American company. We had four years where it wasn’t allowed, we had a woman named Lina Khan running, you know, for the Biden administration, the rules around M&A, and they blocked them. And so people gave up on M&A. President Trump joined, became president for a second term, 47th President of the United States, and he has been very pro-M&A. In fact, inserting himself into it and advising people and asking for certain ones to be approved and others not to be approved. There are some problems there, I guess, in terms of fairness and maybe being too involved and not impartial enough, but net-net, we’re starting to see a lot more M&A and that’s good for the ecosystem because it recirculates cash. Talk a little bit about equity and employee equity and cap tables. We’ve got a lot of founders in the room and in America, we have a, especially in San Francisco, I would say, a cutthroat environment for equity. We have founders who will basically decide, hey, I’m going to do four years at Google, my four years are up, I’m not happy with this equity grant, I think Google’s fully, you know, I think their valuation is fully realized or it’s going to grow more modestly now, which is what happens when companies mature. I’m going to go to Meta. They go to Meta and then they go, oh yeah, I’ve been here for three years, I’ve vested most of my equity, but Uber and Airbnb and Coinbase are giving me a better deal and those are higher growth. Then, oh, I’m going to now, the top thing to do is try to get SpaceX, Anthropic, and OpenAI shares or, and many other AI companies. The expectation here, there isn’t as much of a cutthroat environment. Employees don’t even in some cases understand, and you might be the first person to give them equity. Do they believe you that it has the potential to have value or do they just think this is just like a lottery ticket and they don’t take it as seriously as say American, you know, rank and file management, developers, technical staff where they look at it and go, oh yeah, these are going to be worth something, I’m going to buy a house with this money?

Bilal Kharouni: 38:35 Very interesting. So I think it really depends on the employees. We’ve had some who wants to fight to have more stock options and to have more equity in the company, some less, but we try to really make them understand that our success is shared with all the company. That’s very important for us. But more and more, I think Japanese employees look at that. equity in the companies, so there’s been a lot of talks in the news about how the stock options regulations got eased in Japan. So now definitely, it is more accepted and understood by—

Jason Calacanis: 39:15 What were some technical issues around taxation and the awarding of them?

Bilal Kharouni: 39:19 Yeah, so I’m not really familiar with the topic because that happened just before we really started issuing a lot of stock options. But from what I’ve heard, yeah, it was on top of the taxation, it was also quite hard to grasp the previous framework and now it’s really simplified to just give them.

Jason Calacanis: 39:39 How much do you focus on product-market fit and refining it and improving it at your startup, and how do you know—and how did you know previously—that you were getting product-market fit? What were the early signs of product-market fit that led you to make good decisions? Maybe what were the signs maybe when you were less focused on product-market fit, did you make some mistakes in building things you didn’t need to? Just explore and let’s open up that topic.

Bilal Kharouni: 40:05 It’s quite interesting. So we have these epigenetic services, right? So now we focus really on drug development, but we also used to offer the services to longevity clinics that want to measure aging for their patients. And we actually had quite some growth with the clinics, a lot of prospect, a lot of meetings, but we decided to completely terminate this business. And the reason why was because it felt like a distraction from what will really make the value of the company explode, which is the race for data generation. So we really just focus on improving our methods to have even higher resolution in epigenetics, and the idea is to being able to generate data that nobody else can and from this data derive assets that will give us an unfair advantage that could be new diagnostic, that could be new therapeutic assets. And that’s, I think, what would be the vision of product-market fit, is when we’ll be able to really derive our own IP—our own IPs from the platform that we’re building.

Jason Calacanis: 41:08 So you had short-term quick revenue, some early success, but you looked at it and said, ‘Hey, that’s not going to be an outlier success and it’s not going to accrue significant value to the equity holders, to the corporation.’

Bilal Kharouni: 41:26 More importantly, yeah.

Jason Calacanis: 41:27 And so let’s go for the long value creation, and that’s trading short-term greed and opportunity for long-term greed and opportunity, yeah?

Bilal Kharouni: 41:34 We really believe in the clinical importance of biomarkers of aging in clinics. We didn’t exit the market for that. But what we believe is that we can, if we keep improving our methods to generate data at a higher resolution, lower cost, we might be able to come to clinics with an even cheaper and better product. So we really want to focus on the R&D, really want to focus on the data generation, and then derive even better services when we have the platform built.

Jason Calacanis: 42:00 This is a tension a lot of founders feel early. They’re— There is a certain amount of runway in the bank. You’ve got 18 months, 12 months, and you can pick up some quick revenue, you see ‘oh it extends the runway.’ But it’s not building a long-term business that could be a billion-dollar outcome.

Bilal Kharouni: 42:14 Yeah.

Jason Calacanis: 42:15 And angels might be like ‘whoa, I don’t want my investment to go to zero,’ so an angel investor on your cap table might say, ‘oh yeah, go for that quick revenue’ because they’ve seen too many companies flame out. A VC might tell you, ‘don’t try to make money, just try to build that value. We’ll give you 36 months of runway. We want you to go for the long game.’ And then of course, you have a board of directors, and now you get caught. Maybe you have an angel on the board, maybe you know, you have some people who are nervous from corporates, maybe you have people who are VC’s who they just want the power law. They would rather nine out of ten companies go to zero and one go to a billion than have you know, five of them have 100 million dollar exits because just on a math basis, 500 million versus a billion or two billion dollar outcome, they’re going to push you for that. So have you experienced that tension yet, here in year three or four?

Bilal Kharouni: 42:36 No actually, and I think that one of the reasons why is, in our cap table, so we have angel investors, but they’re all first, well-versed in biotech, and second of all, this is not the first check they sign. So they know how it plays. But also what is important, even before having the approval from your board of directors, you also need to have a consensus inside the company, right? You need to talk with all of the team and just decide ‘this is the company we want to build, this is the risk we want to take, and this is these are the changes we want to have on the world.’

Jason Calacanis: 43:00 I want to go back to one topic I didn’t hit on when we were talking about your company, which is biological age. Yeah, I have a Whoop, I did blood tests with Superpower and Function Health and all these things, and one of them gives me like ‘oh, you’re not sleeping at the same pattern, so you’re a little bit older,’ and then my blood tests are excellent, ‘oh you’re a little younger.’ These are just two different modalities. One is the blood test, one is like sleeping pattern, stress. How am I as a consumer of these products to understand the concept of biological age and how can I actually take action based on that? Because my Whoop’s just saying, ‘go to bed and wake up at the same time every day and you can game your score.’ But I don’t like to go to bed and wake up at the same time. I like to go to a concert or a Knicks game and stay out late and then sleep in. Sometimes I get up really early and want to do a workout. I don’t want to live by that strict of a - and try to game that metric. And I don’t want to take a ton of supplements and try to make my Vitamin D go up just so my blood test can say it. I’m having a hard time making sense of this. What is biological age and what’s the best way to tell it?

Bilal Kharouni: 43:57 Is basically… what is your age? Sorry, it’s basically you look at the biomarker, and it’s looking how you benchmark to a cohort that has It’s similar H. So we can look, for example, at the methylation of your DNA and estimate that you have methylation patterns that is someone of someone who’s like 45 years old. Or we can look at another marker and estimate that your biological age is 55 years old. So it’s really finding biomarkers and then just looking how you benchmark. And what you were mentioning with the Whoop and how to try to game the system, I think is very important because at some point, that’s why actually I’m making a stop for my Oura ring, is because it looks like you’re trying to optimize for biomarkers that can be disconnected from your actual health, from really how you feel. And so for consumers, I would say that the value is really for the trends that actually encourage at a population level people maybe to sleep better, to eat better. But if we look at the biological age and biomarkers of aging for drug development, then you can find some value, right? Because you can actually have a marker that is objective, that is not perfect, but that can really help designing your clinical trials protocol, or that can help you help for your drug discovery.

Jason Calacanis: 46:12 Amazing. Finally, blue zones. Okinawa is one of them, there were some in Italy. I understand there’s been some now research and people went into the blue zones and in some cases people were lying about their age—you heard this story?—because maybe they got some benefits of saying they were a little bit older in some towns, so some of that research has been reversed. But the Japanese people are known for living longer on average, and they’re in some cases living in cities for to a long age. Do—has there been enough research now to understand the truth about these blue zones? And Okinawa, obviously, is one that is legitimate, I believe, and maybe the ones in Italy were the ones that weren’t. Tell me a little bit about the controversy there.

Bilal Kharouni: 46:58 Um, so the papers that was released for the controversy was basically, um, it made an observation that most of the blue zones were the poorest areas of those countries. And so it’s not really intuitive to think that the poorest areas of some countries are where the lifespan are the highest. So they went, did some field trip, and they realized that some people, for example, that we estimated to be 118 years, were just dead and people were collecting the pension, uh, of the family, for example. That being said, in Okinawa and in most of the blue zones, there’s some strong, uh, links is sociability.

Jason Calacanis: 47:40 Sociability. Why would that make somebody live longer? They’re happier? They have lower stress? What is the theory there that socialization correlates with longevity?

Bilal Kharouni: 47:51 Exactly. So I think it’s first, if you have someone who knocks at your door every day to see that you’re in good health, you have someone to actually care for you and therefore you tend to live higher and having healthier behavior. Yeah. And also I think that mentally having someone to look… to look at and to have a regular routine with some people that you appreciate and you to feel the support is actually extremely important to be in a… in good health.

Jason Calacanis: 48:13 Ah.

Bilal Kharouni: 48:14 And unfortunately I know some people who’ve had these really strong supportive networks for years and when this supportive network disappear, they can actually…

Jason Calacanis: 48:26 Yeah. Decline.

Bilal Kharouni: 48:28 Decline, yeah, way extremely fast.

Jason Calacanis: 48:30 Yeah.

Bilal Kharouni: 48:30 So this socialization is… extremely important and I’ve seen it firsthand in Okinawa with some solidarity networks that last for a really long time with people that have been peers for decades and it’s really beautiful to see and as well as diet can make… definitely a difference especially in Italy the Mediterranean diet is…

Jason Calacanis: 48:54 Yeah, yeah, yeah, yeah. And I saw a study last week, and again, this is a very early study and I like to find these research studies as they happen. It said the chances of Alzheimer’s, Parkinson’s were dramatically lower in people who are bilingual or lower in people who are bilingual and knew a second language, and dramatically lower in people who are able to speak four languages or more. And I thought, wow, that’s fascinating. There’s something about the plasticity of the mind that if you speak multiple languages your mind is healthier which then makes sense it’s almost like it’s working out and because it has… and this is… I don’t know if you’ve heard this study that’s just in the last year or so?

Bilal Kharouni: 49:38 I’ve read it, yeah. And it would be interesting to see if blue zones also zones where you have more dialects and therefore…

Jason Calacanis: 49:46 More brain health.

Bilal Kharouni: 49:47 More brain health, yeah.

Jason Calacanis: 49:48 Because that is one of the big diseases, right? You have heart, you have…

Bilal Kharouni: 49:51 Exactly.

Jason Calacanis: 49:52 …and brains and lungs… like there’s like some specific ones that tend to…

Bilal Kharouni: 49:57 The four horsemen of the death.

Jason Calacanis: 49:58 The four horsemen of the death, yeah. And I think these are some of the big ones. Well this has been a fascinating discussion let’s give a big round of applause to our guest! And we’ll do a couple of questions from our founders here. If you have a crisp great question, we’re going to… we have a microphone here, we’d like you to come up to. A great question would be amazing, either about his company or… just about running a company. And so we could use three great questions.

Audience Member: 50:25 Hello, thank you for the talk. Yeah, my question is, um, when you decided to cut one of your services, as you mentioned with Equinox, did you base it on data of the earned or the… what do you call it? The earned and the booked amount, or did you also play into the forecasted one if you’re going to be closing this certain project?

Bilal Kharouni: 50:43 Well, actually, if we were looking at the numbers and if we were looking at the books we would have probably kept the business because it was revenue generating and growing. It was more of strategic question like where do we want to grow the company and where do we really want to focus 100%? In terms of development, and we’ve made the difficult choice of cutting a service that was actually generating cash regularly and predictably to really being able to focus on the R&D and trying to cut distractions for the time being.

Jason Calacanis: 51:14 Alright, great question. And that really is what it’s about. You have only so many cycles as a founder and a founding team, and focus is so important, yeah?

Bilal Kharouni: 51:23 And especially today because… so we do work with AI, we generate data for AI models, but we are not like an AI-first company. And today it feels like every week where you don’t grow exponentially is a week that you might waste forever, I don’t know if that makes sense. It’s just there’s a cost of not growing fast and being ambitious today that is I think higher than ever. And we really want to grow the company as much as we can in a difficult industry where we are… we have to follow the pace of experiments in the lab and we really just want to give us all the force to grow as much as we can and working on the most difficult topics because this is where we will really create value.

Jason Calacanis: 52:08 Yeah. Uh, it’s inherent in the Japanese culture, I believe the term is Kaizen, continual- continuous improvement, yes? Yeah, I’m getting nods. Okay. I pronounced it correctly, yeah? Kaizen. Um, and this is one of the reasons why when I bring investors or angels or venture capitalists and founders and I take them to Japan for the first time and they see everybody really caring about what they do, they don’t realize that the person who has been working on coffee or pasta, or you know, their tailor, or they work in the subway, they’ve been trying to be a little bit better every week for many years. My favorite audio guy, every time he just tries to make the audio 10% better, right? And that spirit is so important and founders have it inherently, but most people don’t and they don’t understand that compounding improvement, just like compounding interest, is one of the most powerful forces in the world. And to your wasted weeks, this is so critical because it’s not just if you waste 10 weeks a year, if you could’ve- could’ve gotten your startup to be 3% more efficient that week and then 3% and- I mean, it compounds and it compounds. And instead of having, you know, that kind of improvement, you’ll just have… phew.

Bilal Kharouni: 53:30 This is what we hope. And- and no, I think we… we are in one of the most exciting times to be a startup. And I don’t think that we can afford to not try to go… push, yeah.

Jason Calacanis: 53:40 You really want to try to accelerate it. And are you- let’s take another question if somebody has one, go ahead and go to the microphone. And while we’re waiting for somebody to go to the microphone with a great question, don’t be bashful here, I know you have questions. Um, if this was America, they would be pushing each other over to get to the microphone to plug their company and you’re being so polite… And bad a plug for their company into the question. But one question for you, I think you know when you look at this improvement, how are you using AI to run the company? And how do you decide to hire the next person or maybe solve those problems with AI?

Bilal Kharouni: 54:20 Um, great question. So as an organization, we are still like AI 1.0, I would say. We don’t use agents, for example. So…

Jason Calacanis: 54:29 Oh wow. No agents? No cron jobs? No agents, no cron jobs. Okay.

Bilal Kharouni: 54:34 Exactly. So we still like have a lot of like lab work that is quite manual. But for AI, yeah, unfortunately like we do hire for example like junior people and interns that have learned, that have a background in machine learning for example, and that we know they can actually use AI the best they can to accelerate their work, yeah.

Jason Calacanis: 55:03 Yeah, this is a term at Amazon, Jeff Bezos and the team over there had called a bar raiser. So you have a group in your company and you say, ‘Oh, we want to add somebody who’s really good at PR, social media, and just doing corporate communications.’ Okay, what do we all know about those topics? And everybody puts it on the table in a document what they know. And then you hire somebody who has a much higher knowledge base than anybody on the team. So when they come in, the bar has been raised. Now we know somebody who really knows how to write a blog post, do a video, do, write a tweet, go on LinkedIn and tell us how to promote there. And then everybody in the organization, the bar’s been raised. Why hire somebody? And sometimes people out of fear of hiring somebody better than themselves would be like, ‘Oh, I don’t want to hire somebody better than me, then the boss is going to like them better and maybe my job’s at risk or they’ll take work away from me.’ But they got everybody to agree, let’s try to hire bar raisers, let’s try to hire the people who can drive the company, you know, higher.

Bilal Kharouni: 56:11 Especially at the beginning, at the start of your company, right? Because you need those people who really going to bring something that the team doesn’t have. So it’s really essential to have bar raisers. And also what is quite great, we have a great example in our engineering team, people who have really solid senior level, with the help of AI, demultiplied the quality of their work and became almost, you know, world-class level as an engineer. So it’s very exciting time, yeah.

Jason Calacanis: 56:35 Let’s take another question from our amazing Founder University founders.

Audience Member: 56:39 Hey, thank you very much for the session. I wanted to know, how do you know the best time to exit? Are there some factors you look at? Are there signs to let you know this is the right time, this is the right company?

Jason Calacanis: 56:53 To sell your company? Yeah. Great.

Bilal Kharouni: 56:55 Um, so for us we have envisioned like three times we could be acquired… And it’s really thinking, okay, if we get acquired now, can we push the company at a much higher valuation in the next couple of years and the next three years? Or is it better to just sell the asset now and let someone else take the hand? So we have tried to build a company that will grow into a platform. A platform is basically will have the engine to generate IP and to generate different assets. And the question for us to exit would be, okay, if company A wants to acquire for assets, do we sell them or do we just want to keep pushing to develop even better assets and more assets to have this compound effect and take the risk of not selling now? Um, so that would be for me the idea that I would have about the exit. It would be really about can we keep generating more IPs and more assets.

Jason Calacanis: 57:55 Yeah, and I would say, when I talk to founders about this and they ask me for my counsel, if the founder um is not having fun and they don’t want to come to the office every day, it’s like going to work is drudgery as opposed to inspiring. If you don’t want to get to the office as soon as possible to start working and you can’t sleep at night because you’re just so engaged, then maybe it’s time to sell. If you’re not or let somebody else run it who is more engaged than you. The second is you get an unreasonable offer. So your company was valued in the last round at 20 million and somebody offers you 200 million. It’s life-changing money for you or your family, then you might have an obligation to take it because it might not come along that often, right? So the unreasonable offer is the second reason. The third reason is if you’re very mission-driven and you say hey, my mission is I want to help people live longer and they come to you and they want to acquire your company and they are the most credible company doing that and they’re going to make you the president of the organization to report directly into the CEO, you might say, you know what? Um, that’s going to take five years out of our mission. We’re going to have unlimited funding, we’ll have unlimited resources and they have unlimited go-to-market. I’d like to do that. And sometimes maybe your business is troubled. So in the case of YouTube, they were under a crazy lawsuit that was going to end the company that no VCs would fund. So they had no choice, right? It was the—that was their fourth option. And what you’re trying to also factor in is if it’s another five years from now and this company goes a 100x, will I have regretted it? And do I want to run this business for the rest of my life? You have to ask yourself, do I want to run this forever? And if you do, then you have to say wow, I will get unreasonable offers, I will get offers that will accelerate the mission, and I’m going to turn them down because I want to independently pursue the mission so greatly that I’m going to stick with it. Uh, so this is a great question. Never tell investors though that you want to sell and make quick— money, because you have to understand from their perspective, you need to look at their portfolio management. Maybe their firm is a 200 million dollar firm that’s going to invest in 30 companies. They expect 25 to go to zero, three to return two or three times their money, and they’re looking for one or two to be outliers. If they have one that’s an outlier and returns 30x, 40x, 50x, maybe they have a 2x fund. If they have two do that, maybe they have a three, four, five x fund, and they’re in the elite venture capital space when they get to three times, four times, five times, and there’s of course outlier success. So you have to understand their motivation. If they invested at your company at 20 million, they’ve got a 200 million dollar fund, and they own 10% of your company. Okay, they own 2 million in equity in your company. If your company gets to 10 billion and they’re diluted 50%, now they own 5%, they get 500 million dollars, you’re a two and a half x company. That’s if they invested just in your company and you become a 10 billion dollar company. Think about how hard venture capital is. That’s how hard it is. That’s why so many people are quitting venture capital and do one or two funds and just quit. So you need to understand what pressure they’re under. Great question. Great companies are bought, not sold. If a great company has got many offers, you can run an auction and what they call a process. A process typically involves a bank or is founder-led with the CFO. They make a list of targets. They say, ‘Hey, we’ve gotten two offers. We want to do our due diligence with our board, and the board has gone out and selected you as one of the people we’re going to talk to. We have 12 people we’re talking to. Would you like to review our company and where we’re at? Would you like to meet our management?’ Of those 12 targets, six say yes, and then you’ve got two offers, and of those six, another three offers come in. Now you have five offers. Now you say, ‘Okay, we’d like everybody to put their bid in, then we’re going to go into the final two bids, and then we’re going to do one more bake off.’ And you explain that bidding process. And so yeah, Roelof told me that at Sequoia when he—yeah—and he said great companies are bought, not sold. If you’re in the selling process and trying to convince people, it’s going to go for a low price. If you have multiple offers, it’s going to go for a high price. And you’ll just know because people will want to hang out with you. All of a sudden, the founder of another company will call you, like Steve Jobs called famously the founder Drew of Dropbox and said, ‘Hey, I would love to hear what you’re up to.’ He’s not calling because he needs more friends. Steve Jobs had enough friends, and if he wanted more friends, he could just pick a celebrity or some artist or the most interesting person in the world and be friends with him. If Steve Jobs wants to meet with you, it’s for that reason. So you know when it’s happening. Great job. Okay, let’s take another question. Now we’re talking! Now the dam has broken. Now we’re talking. Okay.

Audience Member: 1:02:46 Question but, uh, Japan is a land of the robots and there’s a lot of human-robot interaction research here around aging and the use of social robots. So, you know, my question is, if loneliness has a measurable biological impact through stress, inflammation, cognitive decline, do you think that perhaps there’s sufficiently— A sufficiently capable social robot could measurably improve biomarkers of aging?

Jason Calacanis: 1:03:06 Ah, that’s a great question.

Bilal Kharouni: 1:03:08 If the robot can actually create a link with a person and have a feeling of care, I would assume so. And I don’t know if you’ve seen like the dog robots that were recently and there were like some studies that actually showed that there was an affectionate link being created, so I would love to believe that they will be a value for it, yeah.

Jason Calacanis: 1:03:31 And that… Now we’re talking. He has a robot company working on… Now we’ve got in the spirit. He’s got a robotic company that’s working on the software to create companions. Well done. Great question. Alright, let’s take another question. Now we’re talking. Now you guys are acting like Americans. Okay, would you like to promote your company in the form of a question? Go.

Audience Member: 1:03:51 Oh, I’m doing something about A to A, Asian to Asian. But my question’s something different. Okay. I’m curious about your opinion on walking culture. Today Silicon Valley has a very hustle culture, such as you know, 996 or 007, and do you think it is bad for longevity? Or I mean, or sometimes startups should do that kind of you know, resolution.

Jason Calacanis: 1:04:03 That’s a good question. Yeah, the intensity of 996. Which is a Chinese thing, not a Japanese thing, is it?

Bilal Kharouni: 1:04:06 I think so. But Japan also has similar tradition I guess. Especially in, you know, traditional companies in Japan.

Jason Calacanis: 1:04:14 Yeah, you work late nights, yeah.

Bilal Kharouni: 1:04:16 Yes. Okay. Yeah, no, it’s extremely interesting. And actually today I read an article about the Prime Minister Takeuchi, who was saying that she was sleeping between zero to three hours a night for her job. And I personally think that it’s not sustainable. So of course in a startup we have marathon, we have crush, and the 996 is just inevitable. Uh, we work on difficult things and we work on things that also we’re passionate about, right? We have a team that would have the choice to either work in some of the best universities in the world or for some huge biotech startups and they take the choice of building something with us. So usually they have this motivation to just work long hours and multiple days. That being said, as a company at Ike.labs we really value work-life balance and we really value personal time, and we think that in the long run you need to allow some kind of rest. And we’ve seen some companies that were actually taking the biological age of their employees to find out if they were like overworked or not. So if their aging was increasing a bit too fast, that maybe a sign that they might be closer to burnout. Yeah. But definitely, I don’t know if you have an opinion on the workload in Netflix?

Jason Calacanis: 1:06:04 Um, you know, at my firm, I say to folks, try and keep up with me.

Bilal Kharouni: 1:06:08 Yeah.

Jason Calacanis: 1:06:08 I work 60 hours a week, 70 hours some weeks, but I try to enjoy life and I think having a sustainable culture is good. Now sometimes we have intense moments, like we’re kicking off a program. Other times things are a little bit slower. Venture tends to be slower over the holidays because no deals get done between December 15th and January 10th maybe. So you have this nice respite.

Bilal Kharouni: 1:06:27 Mhm.

Jason Calacanis: 1:06:27 And in the summer other VC firms essentially, the VCs go on vacation for weeks and they might be lightly active but they do a lot of travel and they try to enjoy it. For startups, I think you should work extremely hard and try to beat your competition,

Bilal Kharouni: 1:06:45 Mhm.

Jason Calacanis: 1:06:46 but you do need to understand that if you work hard you have to play hard, and then I don’t have a problem with founders who put three or four hard years in, fail,

Bilal Kharouni: 1:06:54 Mhm.

Jason Calacanis: 1:06:55 and then decide to take a year off and kind of explore and recharge their batteries,

Bilal Kharouni: 1:06:59 Mhm.

Jason Calacanis: 1:07:00 and then they come back and I watch them do it again and I’m like super proud of them. It’s an extreme pursuit.

Bilal Kharouni: 1:07:07 Mhm.

Jason Calacanis: 1:07:08 Being a Navy SEAL is an extreme pursuit. Nobody would look at an Olympian or a Navy SEAL or LeBron James and say, ‘Oh my god, that person is like sacrificing like their life, like don’t they, wouldn’t they enjoy eating like more pizza?’

Bilal Kharouni: 1:07:25 Mhm.

Jason Calacanis: 1:07:25 Then it’s like well no they’re an Olympian, they’re trying to set a record, you know for the, you know, and break a four-minute mile, like of course they’re not going to eat pizza and ice cream every day. They’re sacrificing pizza and ice cream to break a world record.

Bilal Kharouni: 1:07:42 Yeah.

Jason Calacanis: 1:07:43 Now if you watch a lot of athletes the first five years after they retire from the NBA, you’re like, ‘Well, they’re definitely eating well.’ You know the body changes completely. But or some of them are just addicted to it and they just stay in shape, but I do think you need to make a very personal choice. And the, and then superimposed on that choice is if you have a partner, if you get married and you have kids now you have a different responsibility. So I’ve seen many people go into their older years, 40-year-old founders, 50-year-old founders with families, and what they do is they’re ruthless about their time at work. So they get up at 5:00 or 6:00 a.m., they do two hours of work, they have breakfast with their kids or drive them to school, they put in like a really intense seven hours, then they have dinner with their families, they watch a movie, or do whatever their family is going to do, and then they get back on their emails at 10:00 o’clock, they pound out another hour. That’s me. Like I am ruthless about my time. I do not waste time on phone calls, like I literally have an enterprise person selling me enterprise software who’s like, ‘I will, let’s just do a quick 20-minute phone call.’ I said, ‘I’m not a phone person, just give me your best fucking price.’ Sorry, I’m in Japan, sorry. Um, just give me your best freaking price and I’ll tell you yes or no. And they’re like, ‘Yeah, but I want to walk you through some products and we’re really competing with this company.’ I was like, ‘I, I just literally said to them, I don’t care. I just want the best price and I’ll make a quick decision. If you want to share anything with me, make a Loom, like please.’ Make me a recorded video of the three new features and send it to me, and make it short and I’ll play it on 2X speed. I’m busy. I got three daughters waiting to go have dinner with me in Tokyo. I have to give them some time too. Right? So I think this is like the philosophy I take. So different times in your—when I was young, I was at the office seven days a week. I made my career. I just said, I am going to out-hustle everybody. Anytime a competitor started, when I had the magazine business, another competitor started a weekly email newsletter and they beat my cadence of once a month, and I went crazy and I told my team we’re doing a daily email newsletter because they kept scooping us. Then we did a daily and then somebody else said, ‘Oh, this other monthly newsletter is doing a conference and they had like 200 people show up.’ I said, ‘What?’ And I said, ‘We have to do a conference and we need to have 2,000 people there.’ And I got 2,000 people to come and pay $1,000 each and I just said anybody who creates a competing product, we have to do it better and we have to crush them and make them feel like they cannot compete. That’s crazy. And I’m still crazy like that, but what I do is I do it in a more thoughtful way and more strategically. And now I say I’m not going to do some projects, I’m just going to be strategic. So Founder University is very strategic for me. We—we know we can get to founders before the other programs, so I just sat and I meditated. How—namaste. How do we get to founders first? And I just came up with a more efficient idea. So efficiency can beat hours, but efficiency and hours can beat everything. So just be ruthless about efficiency and then with hours you have to follow your energy, like this sleeping zero to three hours a night is dumb, because you’ll make more mistakes and then that will work against you. I believe you should get seven hours of sleep even if you’re like a crazy young person. There’s no reason not to, just stop watching TV. Like, who cares about TV and movies, whatever, like just pick one show a year that you love, go see like whatever number of movies. Also you have to be healthy. Like, this is so critical. I—the founders who are unhealthy, and I was unhealthy, I was 40 pounds heavier. When I was unhealthy, I didn’t think as crisply as I do now. When I lost the weight, I was like, my thinking, my energy just totally changed. So. All right, we’ll save some questions for next time. Let’s give it up for Bilal and his company of course is EKEI Labs, E-K-E-I labs dot com. You’re hiring I assume?

Bilal Kharouni: 1:11:26 Yeah.

Jason Calacanis: 1:11:27 And so if you want to live an amazing life in Okinawa or in Tokyo, go to his website. I’m sure there’s a jobs board.

Bilal Kharouni: 1:11:35 Absolutely.

Jason Calacanis: 1:11:37 And you can go check out all the amazing jobs and we’ll see you next time on This Week in Startups. Good job everybody. Okay.